Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Restless Legs Syndrome Overview 6 Therapeutics Development 7 Pipeline Products for Restless Legs Syndrome - Overview 7 Restless Legs Syndrome - Therapeutics under Development by Companies 8 Restless Legs Syndrome - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Restless Legs Syndrome - Products under Development by Companies 12 Restless Legs Syndrome - Companies Involved in Therapeutics Development 13 Alexza Pharmaceuticals, Inc. 13 Galenica Ltd. 14 Hisamitsu Pharmaceutical Co., Inc. 15 Ligand Pharmaceuticals, Inc. 16 Mundipharma International Ltd 17 Omeros Corporation 18 Restless Legs Syndrome - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 (naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 aplindore fumarate - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AZ-008 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ferric carboxymaltose - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 OMS-527 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 ropinirole hydrochloride - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Restless Legs Syndrome - Dormant Projects 37 Restless Legs Syndrome - Discontinued Products 38 Restless Legs Syndrome - Product Development Milestones 39 Featured News & Press Releases 39 May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs 39 Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome 40 Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome 41 Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome 41 Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44

List of Tables Number of Products under Development for Restless Legs Syndrome, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016 13 Restless Legs Syndrome - Pipeline by Galenica Ltd., H2 2016 14 Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 15 Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 16 Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H2 2016 17 Restless Legs Syndrome - Pipeline by Omeros Corporation, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Assessment by Combination Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 27 Restless Legs Syndrome - Dormant Projects, H2 2016 37 Restless Legs Syndrome - Discontinued Products, H2 2016 38 List of Figures Number of Products under Development for Restless Legs Syndrome, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 11 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Targets, H2 2016 21 Number of Products by Stage and Targets, H2 2016 21 Number of Products by Mechanism of Actions, H2 2016 23 Number of Products by Stage and Mechanism of Actions, H2 2016 23 Number of Products by Routes of Administration, H2 2016 25 Number of Products by Stage and Routes of Administration, H2 2016 25 Number of Products by Stage and Molecule Types, H2 2016 27

Alexza Pharmaceuticals, Inc. Galenica Ltd. Hisamitsu Pharmaceutical Co., Inc. Ligand Pharmaceuticals, Inc. Mundipharma International Ltd Omeros Corporation